Skip to main content
| News

Novartis agrees cooperation to fight Covid-19

29.10.2020

A collaboration between Molecular Partners and Novartis has been announced. Molecular Partners will be responsible for the Phase 1 trials for its two therapeutic candidates against coronavirus. If the trials are successful, Novartis will handle the further development, manufacturing and global commercialization.

Novartis has agreed a cooperation with Molecular Partners from Schlieren for the development of its two potential anti-COVID-19 therapeutic candidates. The Basel life sciences corporation has been granted an option to in-license the global rights of Molecular Partners’ two antiviral therapeutic candidates, MP0420 and MP0423. Novartis can exercise the option if the Phase 1 trial being conducted by Molecular Partners from November is successful. The DARPin therapeutics could subsequently receive emergency use approval. Novartis would then be responsible for all further development, manufacturing, distribution and commercialization activities.

According to a Novartis press release, Molecular Partners will receive a cash payment of 60 million Swiss francs under the terms of the agreement. Molecular Partners is eligible to receive a future milestone payment of 150 million francs if Novartis exercises the option to both therapeutic candidates, as well as royalties on sales. However, the biopharma from Schlieren has announced it will forgo royalties in lower income countries.

“Novartis remains unwavering in its support for tackling COVID-19,” said Novartis CEO Vas Narasimhan in the press release. It is clear that this calls for collaborations. This partnership between two Swiss companies could deliver both prophylactic and treatment options. It is therefore “another demonstration of our sustained commitment to addressing one of the greatest health challenges of our times”.

DARPin therapeutics developed by Molecular Partner are a new class of custom-built protein therapeutics based on natural binding proteins. As the press release explains, these have several characteristics that make them “ideally suited for antiviral therapy”: their multi-specific target binding with the potential to prevent viral escape via mutations, the possibility for subcutaneous administration, their long half-life for sustained activity and the potential to bypass cold storage. Unlike conventional monoclonal antibodies, DARPin therapeutics also make “simple, highly scalable bacterial fermentation feasible”. This means that these medicines can be made accessible to patients around the world as quickly as possible. Novartis and Molecular Partners will work together with the Novartis division Sandoz to scale-up manufacturing capacity.

The Swiss government has secured the right to purchase 3.2 million doses of MP0420 if approved for use in Switzerland.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

BeiGene opens European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

BeiGene opens European headquarters in Basel

BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...

Read More
The 25 Best AI Courses in the Basel Area, Germany and France
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation

The 25 Best AI Courses in the Basel Area, Germany and France

Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...

Read More
Engimmune Therapeutics banks 15.5 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Engimmune Therapeutics banks 15.5 million Swiss francs

Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...

Read More
Bionter receives 3 million US dollars in investments
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Bionter receives 3 million US dollars in investments

Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...

Read More
Resistell seeking to further develop test to combat antibiotic resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Resistell seeking to further develop test to combat antibiotic resistance

The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...

Read More
Biotech startup Cimeio receives 46 million Swiss francs for cell therapy
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Biotech startup Cimeio receives 46 million Swiss francs for cell therapy

Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...

Read More
1 2 3 55

Do you have a question? We'd like to hear from you.